Final results from the only European trial demonstrated a 1.4-month median survival improvement with irinotecan compared with etoposide (8.5 versus 7.1 months, P = 0.02) in patients with SCLC. 4 ...
Subgroup analysis suggested that patients with large, localized tumors benefited from the addition of etoposide, whereas patients with metastases did not. There was no difference in EFS between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback